Crosslink, founded in 1989, is a premier early-stage venture capital firm with over $1.3B in assets.  Crosslink partners with founders that are market disrupters and category creators, typically at the Seed-Series A stage, across highly dynamic enterprise and consumer technology sectors. Over its history, Crosslink has had the opportunity to partner with defining companies such as Bleacher Report (acquired by TWX), BuildingConnected (acquired by ADSK), Chime, Coupa (COUP), DataStax, Molekule, Omniture (acquired by ADBE), Personal Capital (acquired by Empower Retirement), Postmates (acquired by UBER), ServiceMax (acquired by GE), Verodin (acquired by FEYE), Vungle (acquired by Blackstone) and Weave.

Crosslink Capital

Neoteny Co., Ltd is a venture capital firm which specializes in growth capital and incubation investments. The firm considers investments in all stages with a preference for early stage. It seeks to invest in the information technology sector.   Neoteny Co., Ltd was founded on December 1999 and is based in Tokyo, Japan.

Neoteny

Liquid2 Ventures provides technology startups with seed-stage investments and is based in San Francisco, California. The firm was founded in 2015 by Joe Montana, Mike Miller, and Michael Ma.

Liquid 2 Ventures

E14 Fund are an investment fund focused on taking the biggest ideas hatched at MIT, deploying them to the real world, and scaling them for greatest impact.  At the E14 Fund, they help bring technologies out of the lab and into the world. Their network of advisors—investors, industry experts, and entrepreneurs—help their companies take prototypes to scale and raise further investment.  The E14 Fund supports companies across diverse fields—from biotechnology and smart cities to consumer electronics and manufacturing. They are a bridge that builds entrepreneurs from MIT and creates the paths to connect them with investors and industry experts who can help them scale. They believe diversity and inclusion are the seeds of innovation. Half of their companies have a female founder, and more than half have founders are from outside the United States.

The E14 Fund

SpringRock Ventures is a venture capital firm that helps entrepreneurs building compelling companies in an evolving sector. The venture capital firm focuses on digital health, devices, services, oral health, SAAS, consumerization/eCommerce of healthcare, IT, wellness, HIPAA and other innovative companies improving general health. They invest in early to late-stage, high growth-potential companies with some demonstrated customer acceptance.  SpringRock Ventures was founded in 2015 and is based in Seattle, Washington, USA.

SpringRock Ventures

Insight Partners is a global software investor that partners with growth-stage technology and software companies. Insight has a deep focus in Fintech, Cybersecurity, AI/ML, DevOps, and Healthcare sectors. Across their people and their portfolio, they encourage a culture around a core belief growth equals opportunity. As of December 31, 2022, the firm has over $75B in regulatory assets under management. Insight Partners has invested in more than 750 companies worldwide and has seen over 55 portfolio companies achieve an IPO.

Insight Partners

General Catalyst is a venture capital firm that provides early-stage and growth equity investments. The company provides ongoing momentum that accelerates ideas, careers, and companies toward standout success.

General Catalyst

March Capital is a venture growth firm headquartered in Santa Monica, California and investing globally since 2014. March identifies entrepreneurs with a provocative vision to companies poised, then dares to go all in by leading rounds with deep conviction and concentration risk. With $1B+ in capital over 4 funds and across 30 market technology companies, March accelerates the digital transformation of Cloud-based software, automation, AI, and IT infrastructure. Its vision is to create a technology investment platform by combining intense sector focus, patience, access to a network (including founding The Montgomery Summit), and portfolio engagement to inspire and accelerate extraordinary companies.

March Capital

America's leading advocate for oral health. The not-for-profit ADA is the nation's largest dental association.

American Dental Association

Harmonic combines an established, successful investment team with proven, world-class tech operators to invest in market-leading growth companies and deliver unparalleled support and guidance toward their success

Harmonic Growth Partners

Overjet

Overjet is the world leader in dental AI. Founded by experts from MIT and Harvard University, Overjet builds artificial intelligence that helps dental organizations give patients the highest quality of care. Our FDA-cleared technology is the first objective standard for making oral health decisions — so that dentists can detect pathologies with precision and educate patients with confidence. To learn more, visit Overjet.com.

Overjet is the dental industry leader in artificial intelligence solutions that enable clinically precise, efficient, and patient-centric oral healthcare. The company's FDA-cleared AI technology analyzes dental X-rays in real-time to detect cavities, quantify bone loss for diagnosing periodontal disease, identify existing restorations and endodontic treatments, and outline these findings to aid dentists in treatment planning. Overjet's software integrates seamlessly into dental practice workflows, providing objective data-driven insights to enhance diagnosis, patient education, and clinical outcomes.

Dental AI Startup Wins Second FDA Clearance To Detect Top Oral Diseases

Overjet's FDA-Cleared Dental A.I. Named to Fast Company's 2023 World Changing Ideas Awards

Overjet Partners with Dental Whale, Expanding AI for 20,000 Practices

OverJet Dental AI

Overjet Enters Canadian Market With Powerful Dental AI to Improve Oral Health

Overjet Dental AI

Overjet AI platform for dentists now available through Benco Dental

Filling or root canal treatment: Ask Overjet AI

Automation in clinical diagnostics to improve speed and accuracy in patient diagnosis and treatment.

Clinical Decision Support Systems

Overjet: Interview With CEO Wardah Inam About The Dental AI Leader Company

Overjet is the dental industry leader in artificial intelligence solutions that enable clinically precise, efficient, and patient-centric oral healthcare. The company's FDA-cleared AI technology analyzes dental X-rays in real-time to detect cavities, quantify bone loss for diagnosing periodontal disease, identify existing restorations and endodontic treatments, and outline these findings to aid dentists in treatment planning. Overjet's software integrates seamlessly into dental practice workflows, providing objective data-driven insights to enhance diagnosis, patient education, and clinical outcomes.
As of May 2023, Overjet's landmark Caries Assist software for detecting and outlining cavities received multiple honors from Fast Company's 2023 World Changing Ideas Awards. The company was also recognized as an honoree in the Midsized Business category for its innovative technology improving oral health. With multiple FDA clearances for its AI solutions, Overjet is transforming dental care through clinically precise and quantified detection of common oral pathologies.
Overjet's AI platform is widely adopted across the dental industry, utilized daily by some of the largest dental organizations, insurers, and educational institutions nationwide. Major dental insurance carriers like Guardian and Delta Dental, covering over 100 million Americans, rely on Overjet's accurate data to streamline claims processing. In August 2022, Overjet expanded into the Canadian market after receiving a Medical Device Establishment License from Health Canada.

<div>
 
 Clover Health is a healthcare company focused on serving Medicare Advantage members. The company leverages its proprietary software platform, the Clover Assistant, to aggregate and analyze patient data from across the healthcare ecosystem. This data-driven approach aims to support clinical decision-making and improve health outcomes for seniors.
 
 
 
 
 Clover Health operates in two segments: Insurance and Non-Insurance. Through its Insurance segment, the company provides PPO and HMO plans to Medicare Advantage members across several states. As of March 2022, Clover Health had approximately 257,000 lives under its management, a significant increase from around 66,000 lives in the first quarter of 2021.
 
 
 
 
 The Clover Assistant is a key component of Clover Health's strategy. This software platform is designed to provide physicians with relevant patient information to facilitate coordinated care. The company reported that in 2021, its Insurance members whose primary care providers (PCPs) utilized the Clover Assistant had a significantly lower medical care ratio (MCR) compared to members whose PCPs did not use the platform.
 
 
 
 
 In its Non-Insurance segment, Clover Health participates in the Centers for Medicare &amp; Medicaid Services' (CMS) Direct Contracting model, which will transition to the ACO Reach model in 2023. This segment involves aligning with Original Medicare beneficiaries through provider attribution or voluntary alignment.
 
 
 
 
 For the full year 2022, Clover Health expected total revenues to range from USD 3.0 billion to USD 3.4 billion, including projected Insurance revenue of USD 1.0 billion to USD 1.1 billion and Non-Insurance revenue of USD 2.0 billion to USD 2.3 billion. The company also anticipated an improvement in its Insurance MCR, falling within the range of 95% to 99%, driven by operational efficiencies, increased risk scores, and lower Covid-19 costs.
 
 
 
</div>

Clover Health

Digital Diagnostics is a healthcare technology company that develops artificial intelligence (AI) systems for disease diagnosis by analyzing medical images. The company's flagship product, LumineticsCore (formerly known as IDx-DR), is an FDA-cleared autonomous AI system designed to detect diabetic retinopathy and diabetic macular edema during a patient encounter without needing a physician to interpret the images. LumineticsCore increases patient access to care by providing diagnostic results at the point-of-care, eliminating the need for an additional appointment for most patients. This enables healthcare providers to close the gap in eye exams for diabetes care by offering a specialty-level diagnostic exam where the patient receives care.
Digital Diagnostics has also developed DermSpot, an AI system for detecting certain types of skin cancer, which is currently for investigational use only. The company aims to create AI diagnostic solutions that improve patient outcomes, increase healthcare productivity, and enhance accessibility and affordability of care. In April 2023, Digital Diagnostics expanded LumineticsCore to Labcorp patient service centers in Alabama.
Key customers and partnerships
In 2022, Digital Diagnostics signed a long-term strategic partnership with Baxter International to help front-line care providers deliver high-quality care and improve outcomes. The company also partnered with ArchWell Health to bring LumineticsCore to ArchWell Health centers across the US.
Additionally, Digital Diagnostics entered into a memorandum of understanding with the Kingdom of Saudi Arabia's Ministry of Investment in 2022 for international expansion.

Digital Diagnostics

Lunit is a leading provider of AI-powered solutions for cancer diagnostics and therapeutics. The company's flagship product, Lunit INSIGHT, is a suite of AI solutions for radiology that has been approved for commercial use in Europe and the UK through the MDR CE and UKCA certifications obtained in November 2022. The suite includes Lunit INSIGHT CXR for chest X-ray analysis and Lunit INSIGHT MMG for mammography analysis. Lunit INSIGHT CXR can detect 10 chest abnormalities, including pulmonary nodules and pneumothorax, with 97-99% accuracy, while Lunit INSIGHT MMG detects breast cancer with 96% accuracy.
After receiving FDA clearance, Lunit's solutions are clinically used in approximately 3,000 hospitals and medical institutions across 40 countries as of March 2024. In April 2024, a study published in European Radiology demonstrated that Lunit INSIGHT MMG could potentially reduce radiologists' workload by nearly 70% and boost cancer detection accuracy by 30.5%, showcasing its ability to enhance operational efficiency and improve patient outcomes.
In May 2024, Lunit completed the acquisition of Volpara Health Technologies, a New Zealand-based company offering software for early cancer detection, for USD 193 million. The acquisition aimed to strengthen Lunit's presence in the US market and leverage Volpara's robust repository of over 100 million medical images to develop innovative solutions for cancer diagnostics.
Key customers and partnerships
Lunit has established strategic partnerships to expand its reach and integrate its AI solutions into healthcare systems worldwide. In March 2024, the company signed supply contracts with Chung Shan Medical University in Taiwan and Gleneagles Hospital in Singapore to provide Lunit INSIGHT CXR and Lunit INSIGHT MMG, respectively. These collaborations aimed to enhance lung and breast cancer detection in the East and Southeast Asian regions.
In November 2023, Lunit partnered with NTT DATA Singapore to introduce Lunit INSIGHT CXR to Singapore's public healthcare system through the AimSG platform, a national medical imaging AI initiative. The solution was piloted at Singapore General Hospital and Changi General Hospital, two major public hospitals, to enhance the efficiency of chest screening and provide innovative medical services with improved accuracy.
Lunit has also collaborated with leading healthcare technology companies, such as GE healthcare, Fujifilm, Philips, and Guardant Health, to deploy its AI products and leverage their distribution networks.

Lunit

Lumeon is a digital health company that provides a cloud-based Care Orchestration platform designed to automate and streamline the care coordination process for healthcare providers. The platform leverages real-time, bi-directional data integration and applies dynamic clinical intelligence to ensure that patients receive the right care at the right time, every time.
Lumeon's Care Orchestration platform acts as a "care traffic control" center, synchronizing disparate data across the care continuum, orchestrating and automating care pathway activities, and delivering relevant information to care teams and patients. By automating routine tasks and workflows, the platform enables care teams to focus on providing direct patient care, working at the top of their licenses.
The platform integrates with electronic health records (EHRs) and other systems, creating a real-time synthetic patient record to inform care decisions. It visualizes care plans, virtualizes monitoring, and automates routine tasks, ultimately reducing manual intervention and associated costs for providers. The platform can be deployed enterprise-wide and applied across various use cases within a healthcare system.
Key features of Lumeon's Care Orchestration platform include real-time bi-directional data integration with EHRs and other systems, automation of care orchestration tasks and workflows, and the ability to present information through multiple modalities, including within EHRs, native interfaces, web portals, and mobile apps.
Lumeon's platform has been deployed by leading healthcare providers in the US and Europe across more than 2,000 care locations, delivering measurable results in as little as 90 days.

Lumeon

Proscia is a software company that develops digital and computational pathology solutions. Its flagship product, Concentriq, is an enterprise pathology platform that serves as a hub for digital pathology data and AI applications. Concentriq bridges the gap between anatomic pathology laboratories and life sciences organizations, enabling real-world pathology data to fuel innovation that enhances patient care.
The platform delivers an open environment to run a range of AI applications, including Proscia's proprietary algorithms and those developed by partners or customers. One such AI solution is DermAI, a dermatopathology module launched in June 2019 to assist laboratories in tasks like case prioritization, automated quality assurance, and enhanced technical component reporting.
In February 2024, Proscia received 510(k) clearance from the FDA for its Concentriq AP-Dx solution for primary diagnosis in clinical settings. This comprehensive diagnostic software streamlines collaboration and helps drive confidence and efficiency gains. As of December 2023, over 10,000 pathologists and scientists, including those at leading diagnostic laboratories and 14 of the top 20 pharmaceutical companies, used Proscia's solutions.
Furthermore, in December 2023, CellNetix Pathology & Laboratories announced a collaboration with Proscia to digitize a portion of its 1 million glass slides per year and adopt AI-powered digital pathology workflows.

Proscia

Software that provides a list of possible diseases based on data collected from patients. Platforms are only used for initial assessments.

Platforms and software that generates alerts based on patient treatment and current status.

Platforms and software that monitor and track treatment plans of patients, identifies possible treatment issues, and suggests alternative treatment options.

Workflow management software that helps clinicians track and follow procedure for operations.

Companies that use GenAI as a core part of their product offering for Clinical Decision Support Systems

Uses digital mediums to generate actionable insights from health data

Clinical Decision Support System providers incorporate GenAI to enhance their systems

In most cases, CDSSs are provided to healthcare providers

Uses IoT to connect databases with medical devices for decision support

Uses AI/ML to output decisions/recommended actions based on databases of medical records

Overjet

Sources

EDGE Insights

About EDGE

Contact Us

Resources

Area of Focus

Technology Research Made Effortless